Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
Travera Inc
Shanghai Zhongshan Hospital
Hoffmann-La Roche
Myeloid Therapeutics
New Phase Ltd.
Amgen
DualityBio Inc.